Back to search
FDAFDA · Food and drugs·Recall number D-0855-2022

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Published May 18, 2022 · Recall initiated: May 2, 2022

Summary

FDA records drug Class II recall D-0855-2022, published May 18, 2022 and initiated May 2, 2022. Recalling firm: Amgen, Inc.; Status: Terminated; Reported quantity: 15,823; Lot: Lots: 1142258, 1143196, Exp. 09/24. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective container: loose crimp defect, potential loss of container integrity.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amgen, Inc.
Distributor
Nationwide in the USA, Egypt and Lithuania.
Lot
Lots: 1142258, 1143196, Exp. 09/24
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01 recalled?

Yes. FDA published recall D-0855-2022 on May 18, 2022. Reported hazard: Defective container: loose crimp defect, potential loss of container integrity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter